Head-to-head evidence
Clobazam (Sympazan) vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor (benzodiazepine site) · full Epilepsy pipeline
Clobazam (Sympazan)
Marketed by Aquestive Therapeutics, Inc.
NCT00518713 · Phase 3 · completed
The trial randomized 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators blinded. The clinical primary endpoint—percent reduction in drop seizures—was significantly favorable for each clobazam dose versus placebo (p=0.0120, p=0.0015, and p<0.0001).
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clobazam (Sympazan)'s landscape · Midazolam (Nayzilam)'s landscape